{
    "organizations": [],
    "uuid": "93dd9cf5dcf9eb52192858bc6f6fd4985914e0d7",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/01/24/business-wire-incyte-to-report-fourth-quarter-and-year-end-financial-results.html",
    "ord_in_thread": 0,
    "title": "Incyte to Report Fourth Quarter and Year-End Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year end 2017 financial results conference call and webcast for 10:00 a.m. ET on Thursday, February 15, 2018.\nThe schedule for the press release and conference call/webcast is as follows:\n• Q4 & YE 2017 Press Release:\nFebruary 15, 2018 at 7:00 a.m. ET • Q4 & YE 2017 Conference Call:\nFebruary 15, 2018 at 10:00 a.m. ET • Domestic Dial-In Number:\n877-407-3042 • International Dial-In Number:\n201-389-0864 • Conference ID Number:\n13675376 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13675376.\nThe live webcast with slides can be accessed at www.incyte.com under For Investors, Events and Presentations and will be available for replay for 30 days.\nAbout Incyte\nIncyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com .\nFollow @Incyte on Twitter at https://twitter.com/Incyte .\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180124005007/en/\nIncyte Corporation\nInvestors\nMichael Booth, DPhil, +1 302-498-5914\nmbooth@incyte.com\nor\nMedia\nCatalina Loveman, +1 302-498-6171\ncloveman@incyte.com\nSource: Incyte Corporation",
    "published": "2018-01-24T16:00:00.000+02:00",
    "crawled": "2018-01-24T17:53:07.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "wilmington",
        "business",
        "wire",
        "incyte",
        "corporation",
        "nasdaq",
        "incy",
        "announced",
        "today",
        "scheduled",
        "fourth",
        "quarter",
        "year",
        "end",
        "financial",
        "result",
        "conference",
        "call",
        "webcast",
        "et",
        "thursday",
        "february",
        "schedule",
        "press",
        "release",
        "conference",
        "follows",
        "q4",
        "ye",
        "press",
        "release",
        "february",
        "et",
        "q4",
        "ye",
        "conference",
        "call",
        "february",
        "et",
        "domestic",
        "number",
        "international",
        "number",
        "conference",
        "id",
        "number",
        "unable",
        "participate",
        "replay",
        "conference",
        "call",
        "available",
        "thirty",
        "day",
        "replay",
        "number",
        "number",
        "international",
        "caller",
        "access",
        "replay",
        "need",
        "conference",
        "id",
        "number",
        "live",
        "webcast",
        "slide",
        "accessed",
        "investor",
        "event",
        "presentation",
        "available",
        "replay",
        "day",
        "incyte",
        "incyte",
        "corporation",
        "wilmington",
        "biopharmaceutical",
        "company",
        "focused",
        "discovery",
        "development",
        "commercialization",
        "proprietary",
        "therapeutic",
        "additional",
        "information",
        "incyte",
        "please",
        "visit",
        "company",
        "website",
        "follow",
        "incyte",
        "twitter",
        "http",
        "view",
        "source",
        "version",
        "http",
        "incyte",
        "corporation",
        "investor",
        "michael",
        "booth",
        "dphil",
        "mbooth",
        "medium",
        "catalina",
        "loveman",
        "cloveman",
        "source",
        "incyte",
        "corporation"
    ]
}